An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
September 1, 2016
End Date
August 31, 2021
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
September 1, 2016
End Date
August 31, 2021